圣诞节

平安夜

HNRNPC Recombinant Monoclonal Antibody CSB-RA010605A0HU

WORLD AIDS DAY Targeting Understanding,Advancing Hope

🦠 #CD24 is a glycosylphosphatidylinositol (GPI)-anchored protein primarily expressed on immune cells, epithelial cells, and tumor cells. It plays a key role in immune regulation, particularly in dampening excessive immune responses. Read more: bit.ly/3Dc2M1O

Amgen’s multi-million dollar investment in GPRC5D-targeted CAR-T therapy highlights its potential to reshape MM treatment. As research advances, could GPRC5D be the future of immunotherapy? Read more: bit.ly/42l1Emy

Recently, Sanofi’s $20M investment in ZT-01 for type 1 diabetes and Novartis’s $745M deal for SSTR2 radiotherapeutics both point to one thing: SSTR2 is emerging as a key target in modern drug development. 👉 Read more: bit.ly/4a1Dlw2

Dr. Lola Zerbib and her team highlight alpelisib, a PI3Kα inhibitor, as a breakthrough for #PIK3CA/TEK-related #VenousMalformations, reducing lesions by 33.4% (PIK3CA) and 27.8% (TEK) in therapy-resistant patients. Learn more: www.nature.com/articles/s41...

🎉 As we celebrate CUSABIO’s 17th Anniversary, we invite you to share your story with us! 📅 Submission Deadline: February 15, 2025 🎁 𝟏𝟎𝟎% 𝐖𝐢𝐧 𝐑𝐚𝐭𝐞: Every approved story wins a prize! 👉 Celebrate with us: bit.ly/3Dnp1BH #CUSABIO17 #Anniversary #Research #ShareYourStory

DDR1 plays key roles in cell proliferation, migration & tumor invasion. Recent research highlights its role in forming a barrier that blocks T cells, helping tumors evade immunity. Inhibiting DDR1 could restore immune cell activity, offering exciting potential for cancer treatment. bit.ly/4iUp7Ry

𝐇𝐞𝐥𝐥𝐨, 𝐁𝐥𝐮𝐞𝐬𝐤𝐲! 🌟 We’re CUSABIO, trusted by researchers worldwide for 17+ years. Our high-quality proteins, antibodies, and ELISA kits support research in cancer, immunology, neuroscience, and more. 🧪 “𝒀𝒐𝒖𝒓 𝒈𝒐𝒐𝒅 𝒑𝒂𝒓𝒕𝒏𝒆𝒓 𝒊𝒏 𝒃𝒊𝒐𝒍𝒐𝒈𝒚 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉.” Follow us for updates and collaboration opportunities!